文献速递临床试验与 GCP基础与转化研究

同种异体CD5特异性CAR-T细胞疗法治疗复发/难治性T细胞急性淋巴细胞白血病:一项1期试验

Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
PubMed 文献 · Nat Med · 2024-10-01

该1期试验评估了CD5基因编辑的CAR-T细胞疗法在19例复发/难治性T细胞急性淋巴细胞白血病患者中的安全性和疗效,其中16例接受输注,10例达到目标剂量1×10^6 kg^-1。所有患者(100%)在第30天达到完全缓解或完全缓解伴血细胞计数不完全恢复,中位随访14.3个月时4例接受移植。结果提示该干预缓解率高,巩固性移植可能减轻迟发性严重感染风险。

要点

  • CD5特异性CAR-T在复发/难治性T-ALL中第30天完全缓解率达100%。
  • 所有输注患者出现3-4级血细胞减少,30天内1例发生3级感染。
  • 中位随访14.3个月,12例未移植者中2例缓解、3例复发、5例死于感染、2例死于血栓性微血管病。

核心结论

  • CD5特异性CAR-T干预对T-ALL患者具有高缓解率。
  • 证据提示巩固性移植可能减轻迟发性严重感染风险。

研究设计与样本

  • 1期试验,纳入19例复发/难治性T细胞急性淋巴细胞白血病患者,其中16例接受输注,10例达到目标剂量1×10^6 kg^-1。
  • CAR-T产品来自既往移植供者(队列A)或新配型供者(队列B)。
  • 主要终点为21天剂量限制性毒性和30天内不良事件;次要终点为缓解、药代动力学和30天后严重不良事件。

主要发现

  • 所有患者(100%)在第30天达到完全缓解或完全缓解伴血细胞计数不完全恢复。
  • 所有输注患者出现3-4级血细胞减少,30天内1例发生3级感染。
  • 中位随访14.3个月,4例接受移植,其中3例缓解、1例死于感染;12例未移植者中2例缓解、3例复发、5例死于感染、2例死于血栓性微血管病。
  • CAR-T细胞持续存在并清除CD5+ T细胞;CD5- T细胞(大多为CD5基因编辑)增加但仍低于正常水平。

临床怎么用

  • 作者认为,CD5特异性CAR-T干预对T-ALL患者具有高缓解率。
  • 作者认为,证据提示巩固性移植可能减轻迟发性严重感染风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL) patients have poor prognoses, due to the lack of effective salvage therapies. Recently, CD7-targeting chimeric antigen receptor (CAR)-T therapies show efficacy in patients with r/r T-ALL, but relapse with CD7 loss is common. This study evaluates a CD5-gene-edited CAR-T cell therapy targeting CD5 in 19 r/r T-ALL patients, most of whom had previously failed CD7 CAR-T interventions. CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Cohort B). Primary endpoints were dose-limiting toxicity at 21 days and adverse events within 30 days. Secondary endpoints were responses, pharmacokinetics and severe adverse events after 30 days. A total of 16 received infusions, 10 at target dose of 1 × 106 kg-1. All encountered grade 3-4 cytopenias and one had a grade 3 infection within 30 days. All patients (100%) achieved complete remission or complete remission with incomplete blood count recovery by day 30. At a median follow-up of 14.3 months, four received transplantation; three were in remission and one died of infection. Of 12 untransplanted patients, 2 were in remission, 3 relapsed, 5 died of infection and 2 of thrombotic microangiopathy. CAR-T cells persisted and cleared CD5+ T cells. CD5- T cells, mostly CD5-gene-edited, increased but remained below normal levels. These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe infection may be mitigated with consolidative transplantation. This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Pan J, Tan Y, Shan L, et al. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nat Med. 2024. PMID: 39354195. doi:10.1038/s41591-024-03282-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。